Cargando…
COVID-19 vaccine induced interstitial lung disease
A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450284/ https://www.ncbi.nlm.nih.gov/pubmed/34580010 http://dx.doi.org/10.1016/j.jiac.2021.09.010 |
_version_ | 1784569607290355712 |
---|---|
author | Yoshifuji, Ayumi Ishioka, Kota Masuzawa, Yuya Suda, Shuntaro Murata, Saori Uwamino, Yoshifumi Fujino, Motoko Miyahara, Hiromi Hasegawa, Naoki Ryuzaki, Munekazu Hoshino, Haruhiko Sekine, Kazuhiko |
author_facet | Yoshifuji, Ayumi Ishioka, Kota Masuzawa, Yuya Suda, Shuntaro Murata, Saori Uwamino, Yoshifumi Fujino, Motoko Miyahara, Hiromi Hasegawa, Naoki Ryuzaki, Munekazu Hoshino, Haruhiko Sekine, Kazuhiko |
author_sort | Yoshifuji, Ayumi |
collection | PubMed |
description | A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes. |
format | Online Article Text |
id | pubmed-8450284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84502842021-09-20 COVID-19 vaccine induced interstitial lung disease Yoshifuji, Ayumi Ishioka, Kota Masuzawa, Yuya Suda, Shuntaro Murata, Saori Uwamino, Yoshifumi Fujino, Motoko Miyahara, Hiromi Hasegawa, Naoki Ryuzaki, Munekazu Hoshino, Haruhiko Sekine, Kazuhiko J Infect Chemother Case Report A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022-01 2021-09-20 /pmc/articles/PMC8450284/ /pubmed/34580010 http://dx.doi.org/10.1016/j.jiac.2021.09.010 Text en © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Case Report Yoshifuji, Ayumi Ishioka, Kota Masuzawa, Yuya Suda, Shuntaro Murata, Saori Uwamino, Yoshifumi Fujino, Motoko Miyahara, Hiromi Hasegawa, Naoki Ryuzaki, Munekazu Hoshino, Haruhiko Sekine, Kazuhiko COVID-19 vaccine induced interstitial lung disease |
title | COVID-19 vaccine induced interstitial lung disease |
title_full | COVID-19 vaccine induced interstitial lung disease |
title_fullStr | COVID-19 vaccine induced interstitial lung disease |
title_full_unstemmed | COVID-19 vaccine induced interstitial lung disease |
title_short | COVID-19 vaccine induced interstitial lung disease |
title_sort | covid-19 vaccine induced interstitial lung disease |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450284/ https://www.ncbi.nlm.nih.gov/pubmed/34580010 http://dx.doi.org/10.1016/j.jiac.2021.09.010 |
work_keys_str_mv | AT yoshifujiayumi covid19vaccineinducedinterstitiallungdisease AT ishiokakota covid19vaccineinducedinterstitiallungdisease AT masuzawayuya covid19vaccineinducedinterstitiallungdisease AT sudashuntaro covid19vaccineinducedinterstitiallungdisease AT muratasaori covid19vaccineinducedinterstitiallungdisease AT uwaminoyoshifumi covid19vaccineinducedinterstitiallungdisease AT fujinomotoko covid19vaccineinducedinterstitiallungdisease AT miyaharahiromi covid19vaccineinducedinterstitiallungdisease AT hasegawanaoki covid19vaccineinducedinterstitiallungdisease AT ryuzakimunekazu covid19vaccineinducedinterstitiallungdisease AT hoshinoharuhiko covid19vaccineinducedinterstitiallungdisease AT sekinekazuhiko covid19vaccineinducedinterstitiallungdisease |